Intervention: Anamorelin hydrochloride
Trial phase: Phase 2
SMILES: CN(C)N(C)C(=O)C1(Cc2ccccc2)CCCN(C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Anamorelin HCl: 100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
Eligibility criteria:
Inclusion Criteria:

Must have incurable, histologically or cytologically documented Non-Small Cell Lung Cancer or Colo-rectal Cancer.
Females and males at least 18 years of age.
Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) unresectable Stage III or IV NSCLC and/or stage III or IV colorectal cancer (CRC) (not amenable to curative resection).
Involuntary weight loss of 5% body weight over a period of 6 months.
Eastern Cooperative Oncology Group (ECOG) performance status 2 at screening.
Estimated life expectancy of greater than 4 months at the time of screening.
Presence and functional use of both hands.
Able to understand and comply with the procedures of the handgrip strength evaluation.
If the patient is a woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 28 days following the last dose of study medication.
Willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures.

Exclusion Criteria:

Other forms of lung cancer.
Women who are pregnant or breast-feeding.
Obesity.
Recent active excessive alcohol or illicit drug use current use of marijuana or history of marijuana use over the previous 6 months.
Severe depression.

Other causes of cachexia such as:

Liver disease (AST or ALT > 3x normal levels)
Renal failure (creatinine > 2.5 mg/dL)
Untreated thyroid disease
Class III-IV CHF
AIDS
Other cancer diagnosed within the past five years other than non-melanoma skin cancer and prostate cancer
Severe COPD requiring use of home O2.
Inability to increase food intake.
Recent administration of highly emetogenic chemotherapy.
Known HIV, active hepatitis B or C (with increased LFTs), or active tuberculosis.
Patients who have received two prior regimens of cytotoxic chemotherapy and are undergoing, or planning to undergo, a third regimen of cytotoxic chemotherapy.

Currently taking prescription medications intended to increase appetite or treat weight loss; these include, but are not limited to:

Testosterone
Androgenic compounds
Megestrol acetate
Methylphenidate
Dronabinol
Current use of steroids or history of use over the previous 6 months except as pre- and post-medications for chemotherapy administration.
Patients unable to readily swallow oral tablets.
An active, uncontrolled infection.
Uncontrolled diabetes mellitus.
Known or suspected brain metastases.
Patients receiving strong CYP3A4 inhibitors.
Patients receiving tube feedings or parenteral nutrition.
Patients with any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements, including the inability to comply with handgrip strength determinations in both hands; for example, pre-existing neurological impairment.
Previous exposure to Anamorelin HCl.
Patients actively receiving a concurrent investigational agent, or any patients that have received an investigational agent within four weeks prior to randomization.
Current use of diuretics or history of intermittent diuretic usage for any reason over the previous 3 months.
History of claustrophobia.
Cachexia deemed by the investigator to be solely due to chemo or radiation treatment